Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
about
Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropionEffect of Rifampin on Thyroid Function Test in Patients on Levothyroxine MedicationThe influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytesPXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic ModelDrug-drug interaction studies: regulatory guidance and an industry perspectivePrescribing clozapine and rifampicin: clinical impact of their interaction.Transporter-mediated drug-drug interactions.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.Selection of antibiotics for meticillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs?Enzyme induction with antiepileptic drugs: cause for concern?Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroEffect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes.The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers.Effects of Rifampin, a potent inducer of drug-metabolizing enzymes and an inhibitor of OATP1B1/3 transport, on the single dose pharmacokinetics of anacetrapib.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.Plasma and Intracellular Pharmacokinetics of Tenofovir in Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects.Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.Concomitant Use of Carbamazepine and Rifampin in a Patient With Mycobacterium avium Complex and Seizure Disorder.PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
P2860
Q30234940-AED08F1A-8138-4A01-9EE6-0D7065B49E9AQ33423486-D87FB175-1629-4EFE-AC6F-EB25B4F5176FQ34085125-DBE08F18-3E2F-495C-8072-757ABDC7E4B1Q34548528-9230DD13-3399-4568-B7C6-2CB89DAE4CA4Q34571070-42B76035-4A91-4D6C-8227-8B385F804774Q35776626-2E3A68BE-BFAA-4EF6-B5D5-EE07BD1216CAQ36247566-29A63094-4595-4E14-A090-D1AC923A4EB0Q36273788-E0F8C5A2-4088-4D4D-9870-48D98EAADB58Q36573335-0BBDE91E-6EEC-4132-A2C2-2C0BA38534A7Q36675727-2B3B9FB8-CC37-42F5-AC67-C7A73D02A4AAQ36947718-8AFF4941-38EF-4EB8-8C06-F0051B909D17Q36951933-1347F6A3-D175-4E0D-92B8-480846D5421DQ36953235-1F99B20F-7333-43E9-903E-F0768B46F01BQ37905033-88D323EC-B3C5-474F-A84A-2EFA52848C7DQ37960129-6D721480-DF13-4070-A31D-F713E8AC3815Q37982099-CD904ABA-DB54-43FC-A2B8-09028607ED98Q38046892-8D9E0EAF-0023-4A3A-A3C1-52D3AE7B46AEQ38963389-1C40A63E-C395-4D91-8D50-AE8522E464C8Q38973113-9730FFD1-42D1-45F6-893E-86913123D395Q39798811-F16D49F0-9AA6-49BA-96D5-42059EED7324Q40220726-25E8581A-D83F-48C1-8AFC-8B7ED5691EC9Q40269155-D2C2B3C9-680B-41F6-99F1-AD57456BB5BEQ42231090-4C58A7A8-E469-429B-8A23-6FF84409665DQ44613516-CF0B6EC8-48B7-42A4-8397-6EB32B9E2A44Q44737065-EE83D1EE-BEEB-4590-853C-AB5FFFD9BB8EQ44893470-0D137855-A133-437D-89B7-504D8AEFE038Q45847034-7FBF2B93-5466-49C6-A927-76E6D17CF8DCQ46932352-BAABA8F9-70FF-4508-946F-9C664C8C3270Q47924035-7A13E4FF-3A43-47B6-A294-5EE9F8FB621DQ48172902-810C334B-CDA6-4233-81FA-E17402007EA8Q48360626-340FABB3-51F9-4E83-B04C-DDAE59F104DDQ48506430-F98FAD0C-6A5C-40F3-873B-58D0CCFFFA75Q50668713-2A08A54E-E17B-4559-912F-61E593ABBDD9Q51694212-9DA00148-1809-4E5A-B249-C28FDC67ACE0Q53109204-F541E2C3-C905-479C-A5D9-0EC7E084EC8AQ54381356-659C9DA2-9606-43C9-81A2-BD1CDDB4521DQ55485640-8C23EB1C-DD89-43AA-B823-9F28A0285DEEQ58758044-DF4CA9AB-E10A-4685-9F67-1FC983D15348
P2860
Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Rifampin's acute inhibitory an ...... drug interaction trial design.
@en
Rifampin's acute inhibitory an ...... drug interaction trial design.
@nl
type
label
Rifampin's acute inhibitory an ...... drug interaction trial design.
@en
Rifampin's acute inhibitory an ...... drug interaction trial design.
@nl
prefLabel
Rifampin's acute inhibitory an ...... drug interaction trial design.
@en
Rifampin's acute inhibitory an ...... drug interaction trial design.
@nl
P2093
P2860
P50
P356
P1476
Rifampin's acute inhibitory an ...... -drug interaction trial design
@en
P2093
J A Wagner
P2860
P304
P356
10.1038/CLPT.2010.271
P407
P577
2010-12-29T00:00:00Z